Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 1, Open-label Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of An Anti-LILRB2 / PD-L1 Bispecific Antibody SPX- 303 In Patients With Solid Tumors
Jacksonville, Fla.,
Rochester, Minn.
Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.
-
A Phase 1/2 Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, And Pharmacokinetic Study Of Q901 Administered Via Intravenous Infusion In Adult Patients With Selected Advanced Solid Tumors With A Cohort Expansion At The Recommended Phase 2 Dose
Scottsdale/Phoenix, Ariz.,
Jacksonville, Fla.,
Rochester, Minn.
The purpose of part one of this study is to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and safety profile of Q901 monotherapy when administered via intravenous (IV) infusion once-weekly (QW) for 4 weeks and once every 2 weeks (Q2W) thereafter. Also, to establish for future clinical development the recommended Phase 2 dose (RP2D) of Q901 monotherapy when administered via IV infusion QW for 4 weeks and Q2W thereafter.
The purpose of part two of this study is to evaluate safety and tolerability and evidence of anticancer activity of Q901 as monotherapy and in combination with pembrolizumab. In Part 2 Cohort 1, an expansion phase at the established RP2D will be undertaken in participants with selected advanced solid tumors. In Part 2 Cohort 2, a safety run in and expansion phase will be undertaken with Q901 at the RP2D administered in combination with pembrolizumab (400 mg Q6W) in participants with advanced solid tumors.
-
A Phase 2, Open-label, Multicenter Study Of IBI363 (PD1-IL2m) In Subjects With Advanced Solid Malignancies
Rochester, Minn.,
Jacksonville, Fla.
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
Contact Us for the Latest Status
-
A Phase 1/2 First-Time-In-Human, Open-Label, Multicenter, Dose Escalation And Expansion Study Of GSK5458514 PSMA Targeting T Cell Engager Alone Or In Combination With Other Anti-Cancer Agents In Adult Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Rochester, Minn.,
Scottsdale/Phoenix, Ariz.
The goal of the study is to evaluate how safe and how well the body handles GSK5458514 when administered in participants with prostate cancer. The study will be conducted in two parts - Part 1 (dose escalation phase) and Part 2 (dose expansion phase).
-
A Phase 2, Open-label, Multicenter Study Of IBI363 (PD1-IL2m) In Subjects With Advanced Solid Malignancies
Scottsdale/Phoenix, Ariz.
This is a Phase 2, open-label, multicenter study designed to evaluate the efficacy, safety and tolerability of IBI363 (study drug) in subjects with advanced, refractory solid malignancies.
.